SCHEMBL5221226

SCHEMBL5221226

Cc1nc2c(cc1O)C[C@@H]1CN(C(=O)OC(C)(C)C)C[C@@H](C)N21

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.39
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38
PIK3CA P42336 5/20 0.37
USP30 Q70CQ3 2/20 0.35
SSTR4 P31391 1/20 0.35
TLR9 Q9NR96 1/20 0.35
PIK3R1 P27986 2/20 0.35
ESR2 Q92731 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
NAMPT P43490 1/20 0.34
SPR P35270 1/20 0.34
NR1H2 P55055 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219682 0.90 GPR119 (0.39) GPR119SMARCA2SMARCA4PBRM1PIK3CA
SCHEMBL5219131 0.88 USP30 (0.38) GPR119SMARCA2SMARCA4PBRM1PIK3CA
SCHEMBL5219194 0.88 GPR119 (0.38) GPR119PIK3CAUSP30SSTR4PIK3R1
SCHEMBL5222463 0.87 GPR119 (0.38) GPR119SMARCA2SMARCA4PBRM1PIK3CA
SCHEMBL5223395 0.87 PDE4B (0.39) GPR119PIK3CATLR9KDM4E
SCHEMBL5220102 0.86 GPR119 (0.39) GPR119SMARCA2SMARCA4PBRM1PIK3CA
SCHEMBL5222905 0.85 P2RX3 (0.40) GPR119PIK3CAUSP30SSTR4PIK3R1
SCHEMBL5217587 0.85 GPR119 (0.40) GPR119PIK3CAKDM4EMAPTTHRB
SCHEMBL5217508 0.85 GPR119 (0.40) GPR119PIK3CAPIK3R1KDM4EMAPT
SCHEMBL5222525 0.85 GPR119 (0.42) GPR119SMARCA2SMARCA4PBRM1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641796-B1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY HOFFMANN LA ROCHE (CH) 2007-06-06 EP disclosed
US-7208494-B2 5HT2c receptor agonists HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
EP-1641796-A1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY F. HOFFMANN-LA ROCHE AG (CH) 2006-04-05 EP disclosed
US-20050026925-A1 5HT2c receptor agonists HOFFMANN-LA ROCHE INC. 2005-02-03 US disclosed
WO-2005000849-A1 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY F. HOFFMANN-LA ROCHE AG (CH) 2005-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026925-A1 5HT2c receptor agonists HTR2C, HTR2A, HTR5A GPR119 17/4885SMARCA2 3117/4885SMARCA4 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.